The clinical-stage innovative biotechnology company, which is focused on the development of novel medicines that can prevent life-threatening infections, noted that Dr Bewick brings 20 years’ experience in business development at public and private biotech companies as well as mid-sized pharma, both in-house and as a consultant.
Most recently, she was vice president, Business Development at Summit Therapeutics, a NASDAQ-listed infectious disease company, leading the out-licensing and in-licensing activities, pipeline positioning and technology valuation. She holds a BSc (Hons) Neuroscience from the University of Edinburgh and a PhD from the University of Bristol.
In a statement, Neil Clark, chief executive officer of Destiny Pharma, said: “I am very pleased to welcome Stephanie to Destiny Pharma. She brings a wealth of experience and a proven track record in business development and deal-making having completed a range of transactions including in the anti-infectives space. Her expertise will be invaluable to Destiny Pharma as we look to maximise the value of our two late-stage clinical assets and in building a world-leading anti-infection company.”
Bewick added: “This is a very exciting time to join Destiny Pharma after such a transformational year. Destiny Pharma has a fantastic XF platform and biotherapeutic/microbiome pipeline with unique late-stage clinical assets. I look forward to working with Neil and the team to progress the vibrant pipeline.”
On Tuesday, Destiny Pharma said its XF-73 Phase 2b clinical trial was fully recruited by the end of 2020, meeting the target timeline.
The company said results of the trial are expected in the first quarter of this year.